Cargando…

Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis

Detalles Bibliográficos
Autores principales: Mortimer, Isabel, Bissell, Lesley-Anne, Hensor, Elizabeth M. A., Kozera, Lukasz, Mackie, Sarah L., Burska, Agata N., Nam, Jackie L., Keen, Helen, Villeneuve, Edith, Donica, Helena, Buch, Maya H., Conaghan, Philip G., Emery, Paul, Morgan, Ann W., Andrews, Jacqueline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735716/
https://www.ncbi.nlm.nih.gov/pubmed/31329965
http://dx.doi.org/10.1093/rheumatology/kez114
_version_ 1783450399708020736
author Mortimer, Isabel
Bissell, Lesley-Anne
Hensor, Elizabeth M. A.
Kozera, Lukasz
Mackie, Sarah L.
Burska, Agata N.
Nam, Jackie L.
Keen, Helen
Villeneuve, Edith
Donica, Helena
Buch, Maya H.
Conaghan, Philip G.
Emery, Paul
Morgan, Ann W.
Andrews, Jacqueline
author_facet Mortimer, Isabel
Bissell, Lesley-Anne
Hensor, Elizabeth M. A.
Kozera, Lukasz
Mackie, Sarah L.
Burska, Agata N.
Nam, Jackie L.
Keen, Helen
Villeneuve, Edith
Donica, Helena
Buch, Maya H.
Conaghan, Philip G.
Emery, Paul
Morgan, Ann W.
Andrews, Jacqueline
author_sort Mortimer, Isabel
collection PubMed
description
format Online
Article
Text
id pubmed-6735716
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-67357162019-09-16 Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis Mortimer, Isabel Bissell, Lesley-Anne Hensor, Elizabeth M. A. Kozera, Lukasz Mackie, Sarah L. Burska, Agata N. Nam, Jackie L. Keen, Helen Villeneuve, Edith Donica, Helena Buch, Maya H. Conaghan, Philip G. Emery, Paul Morgan, Ann W. Andrews, Jacqueline Rheumatology (Oxford) Letters to the Editor Oxford University Press 2019-09 2019-04-16 /pmc/articles/PMC6735716/ /pubmed/31329965 http://dx.doi.org/10.1093/rheumatology/kez114 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Letters to the Editor
Mortimer, Isabel
Bissell, Lesley-Anne
Hensor, Elizabeth M. A.
Kozera, Lukasz
Mackie, Sarah L.
Burska, Agata N.
Nam, Jackie L.
Keen, Helen
Villeneuve, Edith
Donica, Helena
Buch, Maya H.
Conaghan, Philip G.
Emery, Paul
Morgan, Ann W.
Andrews, Jacqueline
Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis
title Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis
title_full Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis
title_fullStr Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis
title_full_unstemmed Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis
title_short Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis
title_sort improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735716/
https://www.ncbi.nlm.nih.gov/pubmed/31329965
http://dx.doi.org/10.1093/rheumatology/kez114
work_keys_str_mv AT mortimerisabel improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis
AT bisselllesleyanne improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis
AT hensorelizabethma improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis
AT kozeralukasz improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis
AT mackiesarahl improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis
AT burskaagatan improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis
AT namjackiel improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis
AT keenhelen improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis
AT villeneuveedith improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis
AT donicahelena improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis
AT buchmayah improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis
AT conaghanphilipg improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis
AT emerypaul improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis
AT morganannw improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis
AT andrewsjacqueline improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis